martes, 25 de febrero de 2020

Safety concerns regarding Novartis’s new eye drug boost Regeneron stock

Safety concerns regarding Novartis’s new eye drug boost Regeneron stock

Daily Recap

STAT Plus: Safety concerns regarding Novartis’ new eye drug boost Regeneron stock

By MATTHEW HERPER


VANESSA BUMBEERS/UNSPLASH
The American Society of Retina Specialists said some patients were experiencing both a known side effect and a new one after being treated with Beovu.

No hay comentarios: